Don't Just Read the News, Understand It.

Published 2 days ago • loading... • Updated 1 day ago

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog at American Diabetes Association's 85th Scientific Sessions

Summary by Charleston Gazette-Mail

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes and overweight, non-obese individualsPreclinical data for BGM1812 supports further development as next-generation amylin analog for obesity…

46 Articles

46 Articles

All

Left

5

Center

16

Right

3

+44 Reposted by 44 other sources

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog at American Diabetes Association's 85th Scientific Sessions

2 days ago

Read Full Article

presseportal.de

BrightGene Presents Positive Phase 2 Data for the Dual GLP-1R/GIPR Agonist for Weight Regulation and Treatment of Type 2 Diabetes as Well as Preclinical Data for a New Amyline Analogue at the 85 Scientific Sessions of the American Diabetes Association

Bright Gene - Suzhou, China (ots/PRNewswire) - - The Phase 2 data raise the best-in-class potential of ...

1 day ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources46

Leaning Left5Leaning Right3Center16Last Updated19 hours agoBias Distribution

67% Center

Bias Distribution

67% of the sources are Center

67% Center

+11

Untracked bias

+13

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

WTWO News broke the news in 2 days ago on Monday, June 23, 2025.

Sources are mostly out of (0)

Similar News Topics

Similar News Topics